Bone-targeting agents were 2011's top story
Wednesday 1 February 2012
Dr Lee Schwartzberg argues that bone-targeting agents were the most important development of 2011 for supportive car oncology. Because bone is a very common metastatic site for various different types of cancers, bone health is an important research area. He praises the use of denosumab in patients receiving hormonal deprivation therapy (which can lead to bone loss).
>> http://www.oncologystat.com/viewpoints/interviews/Dr_Lee_Schwartzberg_Bone_Targeted_Agents_Were_Last_Years_top_Story_in_Supportive_Care.html;jsessionid=C8740D0116A7EFD36102351626DB4B9D
European Oncology Nursing SocietyAvenue E. Mounier 83
B-1200 Brussels
Belgium
Tel: +32 (0)2 779 9923
Fax: +32 (0)2 779 9937
eons.secretariat@cancernurse.eu